Table 3.
The effectiveness of neuraminidaze inhibitors in the 2009–2010 and 2010–2011seasons evaluated by duration of fever
| Duration of fever after the first dose, hour | 2009–2010 | 2010–2011 | P value between | |||||
|---|---|---|---|---|---|---|---|---|
| A(H1N1) pdm09 (a) | A(H1N1) pdm09 (b) | A(H3N2) (c) | B (d) | (a) and (b) | (b) and (c) | (c) and (d) | (b) and (d) | |
| Oseltamivir | 23·1 ± 12·0 (158) | 26·5 ± 10·6 (30) | 32·0 ± 19·8 (36) | 35·7 ± 25·7 (36) | NS | NS | NS | NS |
| Zanamivir | 26·6 ± 15·0 (207) | 29·6 ± 18·2 (59) | 33·0 ± 22·1 (22) | 30·9 ± 16·8 (19) | NS | NS | NS | NS |
| Laninamivir | n.a | 25·0 ± 15·0 (103) | 30·9 ± 21·1 (33) | 38·5 ± 26·3 (36) | NS | NS | <0·01 | |
() number of patients.
Fourteen patients [5 with A(H1N1)pdm09, 7 with A(H3N2), and 2 with B] to whom peramivir was administered in the 2010–2011 season were excluded from this analysis.